Skip to content

Pulmonx Corporation LUNG Change in Deferred Revenue

Change in Deferred Revenue at other companies

Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
-$41K-141%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$1.38M+9,957%
Mannkind logo
MannkindMNKD
-$4.88M-9.6%
Inogen logo
InogenINGN
-$846K+4.3%

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-47.3%
Enterprise value$50.17M-43.5%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's change in deferred revenue?
Pulmonx Corporation (LUNG) reported change in deferred revenue of $14K in Q1 2026.
How has Pulmonx Corporation's change in deferred revenue changed year-over-year?
Pulmonx Corporation's change in deferred revenue increased by 275.0% year-over-year, from -$8K to $14K.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.